Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.64 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | FUBP1 | Q96AE4 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1593778 | 0.86 | PTGES2 (0.67) | GAAL3MBTL1PTGES2ALDH1A1POLB | |
| SCHEMBL2633819 | 0.86 | GAA (0.67) | GAAL3MBTL1PTGES2ALDH1A1POLB | |
| SCHEMBL7147449 | 0.85 | L3MBTL1 (0.48) | GAAL3MBTL1PTGES2ALDH1A1POLB | |
| SCHEMBL1594800 | 0.84 | GAA (0.61) | GAAL3MBTL1PTGES2ALDH1A1POLB | |
| SCHEMBL1594279 | 0.80 | GAA (0.65) | GAAL3MBTL1PTGES2ALDH1A1POLB | |
| SCHEMBL3473873 | 0.80 | PTGES2 (0.63) | GAAL3MBTL1PTGES2ALDH1A1POLB | |
| SCHEMBL3473539 | 0.79 | PTGES2 (0.65) | GAAL3MBTL1PTGES2ALDH1A1POLB | |
| SCHEMBL3472654 | 0.78 | PTGES2 (0.64) | GAAL3MBTL1PTGES2ALDH1A1POLB | |
| SCHEMBL3472410 | 0.78 | PTGES2 (0.64) | GAAL3MBTL1PTGES2ALDH1A1POLB | |
| SCHEMBL16502999 | 0.78 | PTGES2 (0.64) | GAAL3MBTL1PTGES2ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10800730-B2 | Complex and structurally diverse compounds | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190152891-A1 | COMPLEX AND STRUCTURALLY DIVERSE COMPOUNDS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-05-23 | — | — | US | disclosed |
| US-10081592-B2 | Complex and structurally diverse compounds | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-09-25 | — | — | US | disclosed |
| EP-2188272-B1 | PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND NV (BE) | 2016-02-24 | — | — | EP | disclosed |
| US-20150274638-A1 | COMPLEX AND STRUCTURALLY DIVERSE COMPOUNDS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-10-01 | — | — | US | disclosed |
| US-8722681-B2 | N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases | NV REMYND (BE) | 2014-05-13 | — | — | US | disclosed |
| WO-2013142873-A2 | COMPLEX AND STRUCTURALLY DIVERSE COMPOUNDS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-09-26 | — | — | WO | disclosed |
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2012-08-02 | — | — | US | disclosed |
| WO-2010146236-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORP. (FI) | 2010-12-23 | — | — | WO | disclosed |
| WO-1999016751-A1 | BENZAMIDINE DERIVATIVES AS FACTOR XA INHIBITORS | MERCK PATENT GMBH (DE) | 1999-04-08 | — | — | WO | disclosed |
| EP-0699191-B1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORP (US) | 1998-12-16 | — | — | EP | disclosed |
| EP-0870764-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1998-10-14 | — | — | EP | disclosed |
| EP-0819125-A1 | THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1998-01-21 | — | — | EP | disclosed |
| US-5594021-A | VASOCONSTRICTORS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1997-01-14 | — | — | US | disclosed |
| US-5591761-A | Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1997-01-07 | — | — | US | disclosed |
| US-5571821-A | CARDIOVASCULAR DISORDERS TO MODULATE ENDOTHELIN, HYPOTENSIVE AGENTS AND VASOCONSTRICTION | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1996-11-05 | — | — | US | disclosed |
| WO-1996031492-A1 | THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1996-10-10 | — | — | WO | disclosed |
| EP-0699191-A1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1996-03-06 | — | — | EP | disclosed |
| WO-1994027979-A1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | IMMUNOPHARMACEUTICS, INC. (US) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274638-A1 | COMPLEX AND STRUCTURALLY DIVERSE COMPOUNDS | CYP11A1, LSS, CYP17A1 | GAA 985/4885L3MBTL1 4582/4885PTGES2 2819/4885 |
| US-10081592-B2 | Complex and structurally diverse compounds | CYP11A1, LSS, CYP17A1 | GAA 1321/4885L3MBTL1 4627/4885PTGES2 2715/4885 |
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | ITGA1, ITGB1, ITGA2B | GAA 4118/4885L3MBTL1 4803/4885PTGES2 803/4885 |
| US-10800730-B2 | Complex and structurally diverse compounds | CYP11A1, LSS, CYP17A1 | GAA 985/4885L3MBTL1 4582/4885PTGES2 2819/4885 |
| US-20190152891-A1 | COMPLEX AND STRUCTURALLY DIVERSE COMPOUNDS | CYP11A1, LSS, CYP17A1 | GAA 985/4885L3MBTL1 4582/4885PTGES2 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.